Novodiag® Bacterial GE+, a New Diagnostic Test for on-Demand Detection of Bacterial Pathogens
Mobidiag, a Finnish molecular diagnostics company, today announced the launch of Novodiag® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currently used culture methods.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180416005997/en/
Novodiag® Bacterial GE+, molecular diagnostic test for on-demand detection of bacterial pathogens (Photo: Mobidiag)
“The new Novodiag Bacterial GE+ cartridge can identify dozens of targets, including the majority of bacteria causing diarrhea. Thanks to its simplified and optimized workflow, our fully automated Novodiag solution can support early decision making prior to any treatment delivery and improve patient care by managing infections accordingly” explains Tuomas Tenkanen. “We are very proud to now offer the first syndromic test compatible with our Novodiag system. Our ambition is to make accessible one of the most relevant range of test panels. We are currently working on extending our product line and address among others the detection of antibiotic resistances to improve the correct use of antibiotics”.
Novodiag® Bacterial GE+ test is now available directly through Mobidiag and local distributors. For more information, visit our product page.
About Novodiag
®
(CE-IVD)
The
Novodiag solution allows direct analysis of a patient sample placed in a
disposable cartridge and delivers comprehensive results in about an
hour. Combining qPCR and microarray technologies, Novodiag offers an all
in one solution for on-demand targeted and syndromic testing.
This
molecular diagnostic solution offers an easy to use and cost-efficient
method, with very limited hands-on-time and without the need for much
technical expertise. Novodiag is suitable for all test volumes and on
demand testing for clinical laboratories.
Learn
more about Novodiag.
About Mobidiag Ltd.
Established in 2000, Mobidiag develops
and commercializes innovative solutions to advance the diagnosis of
infectious diseases and serves the European clinical diagnostics market
since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D
center in France and subsidiaries in UK and Sweden.
Combining
Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line
of products for fast, reliable and cost-efficient diagnostics for
infectious diseases and antibiotic resistances. Mobidiag is able to
cover all laboratories requirements no matter their size, throughput and
centralized/ decentralized organization.
To learn more, visit mobidiag.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180416005997/en/
Contact information
Mobidiag
Dorothee Allard, +33 1 55 25 17 13
marketing@mobidiag.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logo Established for the “Japan Creator Support Fund” to Support the Global Success of Japan’s Next-Generation Creators and Artists30.6.2025 09:00:00 EEST | Press release
The Japan Arts Council (President: Mariko Hasegawa), with funding from the Agency for Cultural Affairs, has established the Japan Creator Support Fund to support projects nurturing Japan’s diverse creators and artists, and to support cultural facilities’ function enhancement. We are pleased to announce that the logo for the Fund has been established and that the English-language global website, which is promoting this project overseas, has been officially launched on Monday, June 30, 2025. A promotional video for international audiences is also now available on the website. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627404244/en/ From the top left are the individual logos for the following support programs: the Creator & Artist Development Support Program [FOR CREATORS], the Support Program for Cultural Facilities Function Enhancement [FOR CULTURAL FACILITIES], the Creator Support Program (Program Development & Implem
From Waste to Strategic Metals: Circular Materials Achieves First Industrial-Scale Recoveries Under the Critical Raw Materials Act30.6.2025 09:00:00 EEST | Press release
Circular Materials announces two major milestones under the Critical Raw Materials Act: the recovery from industrial wastewater of the first kilogram of ruthenium and the first ton of nickel, preventing the release of heavy metals into the environment. These results were secured through strong collaborations with two leading companies in surface treatments: LEM, core company of the LEM INDUSTRIES Group, specialized in the luxury sector, and Argos Surface Technologies Group, a leader in industrial coatings. This success comes just a few months after the European Commission recognized Recover-IT as a strategic project, confirming the pivotal role of Circular Materials in securing critical raw material supplies, increasing recycling, and reducing the EU’s dependence on imports. Ruthenium and Nickel: crucial metals for a sustainable future Ruthenium, a noble metal from the platinum group, is essential for cutting-edge sectors such as advanced electronics, green hydrogen production, fine ch
SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom